BioCatalyst

EYPT — EyePoint, Inc. catalysts

2 verified catalyst event(s) for EyePoint, Inc. (ticker EYPT). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-08-01 — A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (L · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
 READOUT
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration
Phase 3 · Wet Age Related Macular Degeneration, wAMD
 EYPT EyePoint, Inc. EYP-1901, Aflibercept (2.0 mg) ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-10 (month)
in 3mo
ESTIMATED
 READOUT
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration
Phase 3 · Wet Age Related Macular Degeneration, wAMD
 EYPT EyePoint, Inc. EYP-1901, Aflibercept (2.0 mg) ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.